Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, Peyrin-Biroulet L. Fumery M, et al. Among authors: altwegg r. Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00423-3. doi: 10.1016/j.cgh.2024.04.016. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38729389
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.
Hupé M, Streichenberger A, Wils P, Arab N, Serrero M, Amiot A, Bozon A, Vuitton L, Fumery M, Altwegg R, Nachury M, Hébuterne X, Yzet C, Coban D, Dodel M, Bazoge M, Pereira B, Buisson A. Hupé M, et al. Among authors: altwegg r. Dig Liver Dis. 2024 Jan 27:S1590-8658(24)00200-7. doi: 10.1016/j.dld.2024.01.181. Online ahead of print. Dig Liver Dis. 2024. PMID: 38281870
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
Fear of COVID-19 Predicts Depression, Anxiety and Post-Traumatic Stress Disorders in Patients with Implantable Cardioverter Defibrillators and Is Mediated by Positive and Negative Affects-A Cross-Sectional Study.
Dörner M, von Känel R, Pazhenkottil AP, Altwegg R, Nager L, Attanasio V, Guth L, Zirngast S, Menzi A, Princip M, Hackl-Zuccarella C. Dörner M, et al. Among authors: altwegg r. J Clin Med. 2023 Oct 31;12(21):6884. doi: 10.3390/jcm12216884. J Clin Med. 2023. PMID: 37959349 Free PMC article.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.
Dupuis-Girod S, Rivière S, Lavigne C, Fargeton AE, Gilbert-Dussardier B, Grobost V, Leguy-Seguin V, Maillard H, Mohamed S, Decullier E, Roux A, Bernard L, Saurin JC, Saroul N, Faure F, Cartier C, Altwegg R, Laccourreye L, Oberti F, Beaudoin M, Dhelens C, Desvignes C, Azzopardi N, Paintaud G, Hermann R, Chinet T. Dupuis-Girod S, et al. Among authors: altwegg r. J Intern Med. 2023 Dec;294(6):761-774. doi: 10.1111/joim.13714. Epub 2023 Aug 23. J Intern Med. 2023. PMID: 37592715 Clinical Trial.
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif.
Guillo L, Savoye G, Amiot A, Gilletta C, Nachury M, Dib N, Bourreille A, Roblin X, Caillo L, Allez M, Picon L, Hébuterne X, Seksik P, Chupin A, Buisson A, Brixi H, Altwegg R, Simon M, Amil M, Laharie D, Bouguen G, Serrero M, Elgharabawy Y, Peyrin-Biroulet L; EXTRA Study Group. Guillo L, et al. Among authors: altwegg r. Clin Transl Gastroenterol. 2023 Dec 1;14(12):e00607. doi: 10.14309/ctg.0000000000000607. Clin Transl Gastroenterol. 2023. PMID: 37523417 Free PMC article.
142 results